Weed rescheduled by June 30?

Marijuana remains classified as Schedule I on the official DEA website as of March 24, 2026, with no final rescheduling rule published in the Federal Register despite Trump's December 2025 executive order directing expedited action; the bureaucratic rulemaking process, including notice, comment periods, and finalization, makes completion by June 30 unlikely given no progress in the past three months. The AI analysis correctly identifies No as undervalued at 80 cents, as the true probability of No is near-certain (>95%) due to procedural delays, providing a strong, low-risk edge. Current facts confirm no rescheduling has occurred post-market open (Feb 7), and credible reporting shows the process stalled.

Web searches confirm marijuana is still Schedule I per DEA website, with no final rescheduling rule as of March 2026, despite Trump's Dec 2025 directive; reports highlight delays from hearings and DEA hesitation, pushing timelines past 2026. This supports the analyst's view that Yes (20%) is overpriced, with true prob Yes <20% (No >80%), providing actionable edge on No shares at $0.80 amid low-volume market. Short timeframe to June 30 yields strong risk-adjusted return potential.

Current reporting from January 2026 confirms that despite President Trump's December 2025 executive order, the DEA rescheduling process remains in a 'pending' status with no briefing schedule even set for the required administrative hearings. Given the mandatory formal rulemaking steps under the Controlled Substances Act—including administrative law judge hearings, public comment periods, and final agency review—it is highly improbable the process will conclude by June 30, 2026, making the 80% 'No' price a significant undervaluation of the actual bureaucratic hurdles.